CTIC insider filings
CTI BIOPHARMA CORP — 20 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-06-28. Screen CTIC transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for CTIC between 2026-07-10 and 2026-10-08. The table below lists the most recent filings on record.
Recent insider filings — CTI BIOPHARMA CORP
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-06-28 | 4 | BVF PARTNERS L P/IL — Director, 10% owner BIOTECHNOLOGY VALUE FUND L P — Director, 10% owner BVF I GP LLC — Director, 10% owner BIOTECHNOLOGY VALUE FUND II LP — Director BVF II GP LLC — Director Biotechnology Value Trading Fund OS LP — Director BVF Partners OS Ltd. — Director BVF GP HOLDINGS LLC — Director, 10% owner BVF INC/IL — Director, 10% owner LAMPERT MARK N — Director, 10% owner | Code (U): 3,989,130 @ $9.10 · Code (U): 2,595,239 @ $9.10 · Code (U): 702,505 @ $9.10 · Code (U): 1,526,147 @ $9.10 · Code (U): 43,139 @ $9.10 · Code (U): 1,594 (derivative) · +12 more | EDGAR |
| 2023-06-26 | 4 | Fong James K — EVP & Chief Commercial Officer | Code (U): 3,565 @ $9.10 · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 8,250 (derivative) · Disposition to issuer (D): 58,750 (derivative) · Disposition to issuer (D): 23,340 (derivative) · Disposition to issuer (D): 188,000 (derivative) · +4 more | EDGAR |
| 2023-06-26 | 4 | Parks Diane L. — Director | Disposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) | EDGAR |
| 2023-06-26 | 4 | Tuckson Reed Vaughn — Director | Code (U): 48,639 @ $9.10 · Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 126,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · +2 more | EDGAR |
| 2023-06-26 | 4 | Metzger Michael A — Director | Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 63,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) | EDGAR |
| 2023-06-26 | 4 | PERRY MATTHEW D — Director | Code (U): 43,139 @ $9.10 · Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · +1 more | EDGAR |
| 2023-06-26 | 4 | Parkinson David Ross — Director | Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 126,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · +1 more | EDGAR |
| 2023-06-26 | 4 | Fischer Laurent — Director | Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 126,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · +1 more | EDGAR |
| 2023-06-26 | 4 | Craig Adam R — President and CEO, Director | Code (U): 31,470 @ $9.10 · Disposition to issuer (D): 1,200,000 (derivative) · Disposition to issuer (D): 450,000 (derivative) · Disposition to issuer (D): 475,000 (derivative) · Disposition to issuer (D): 600,000 (derivative) · Disposition to issuer (D): 470,054 (derivative) · +4 more | EDGAR |
| 2023-06-26 | 4 | KIRSKE DAVID — EVP, Chief Financial Officer | Code (U): 17,547 @ $9.10 · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 315,000 (derivative) · Disposition to issuer (D): 83,396 (derivative) · Disposition to issuer (D): 270,216 (derivative) · Disposition to issuer (D): 340,000 (derivative) · +3 more | EDGAR |
| 2023-04-07 | 4 | Parks Diane L. — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2023-04-07 | 4 | Tuckson Reed Vaughn — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2023-04-07 | 4 | Metzger Michael A — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2023-04-07 | 4 | PERRY MATTHEW D — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2023-04-07 | 4 | Parkinson David Ross — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2023-04-07 | 4 | Fischer Laurent — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2023-04-07 | 4 | BVF PARTNERS L P/IL — Director, 10% owner BIOTECHNOLOGY VALUE FUND L P — Director, 10% owner BVF I GP LLC — Director, 10% owner BIOTECHNOLOGY VALUE FUND II LP — Director BVF II GP LLC — Director Biotechnology Value Trading Fund OS LP — Director BVF Partners OS Ltd. — Director BVF GP HOLDINGS LLC — Director, 10% owner BVF INC/IL — Director, 10% owner LAMPERT MARK N — Director, 10% owner | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2023-03-16 | 4 | Fong James K — EVP & Chief Commercial Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-03-16 | 4 | Craig Adam R — President and CEO, Director | Grant/award (A): 900,000 (derivative) @ $0 | EDGAR |
| 2023-03-16 | 4 | KIRSKE DAVID — EVP, Chief Financial Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — CTI BIOPHARMA CORP
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-06-26 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-30 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-03-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CTIC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →